November 1, 2012
Syngenta, Novozymes sign commercial agreement to commercialise Taegro？？
Press release
An exclusive global marketing and distribution agreement to commercialise Taegro？？, a fermented biological fungicide based on a naturally occurring bacterium Bacillus subtilis, has been signed between Syngenta and Novozymes.
It offers growers broad-spectrum disease control at very low application rates in a variety of crops. Its multiple modes of action make it highly complementary to Syngenta''s extensive fungicide portfolio.
In April, Syngenta and Novozymes announced a global agreement to commercialise the Novozymes technology JumpStart？？, a seed-applied biological that increases phosphate solubility in the soil.
John Atkin, Chief Operating Officer, said, "We are delighted to enter into another agreement to commercialise a Novozymes technology. Having worldwide commercial rights for Taegro will further strengthen our ability to offer high-performing integrated crop solutions."
Thomas Videb？|k, Executive Vice President Novozymes, commented, "This collaboration matches Syngenta''s global market strength and leading position within fungicides and integrated solutions with Novozymes'' deep know-how on sustainable, bio-based technologies."
Expanding the existing registrations of Taegro in the US, the companies aim to offer the technology to growers around the world for use on a broad range of crops. Financial details about the agreement were not disclosed.
Syngenta is one of the world''s leading companies with more than 26,000 employees in over 90 countries dedicated to their purpose of bringing plant potential to life.